

**ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)**

4 May 2018

**IMMUTEP TO PRESENT AT 2018 ASCO ANNUAL MEETING**

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, being held 1-5, June 2018 in Chicago, Illinois.

Details of the poster presentations in relation to Immutep's lead product candidate, eftilagimod alpha (also known as IMP321) are as follows:

**Abstract Number and Title:** 1050, "Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II."

**Poster Session:** Breast Cancer—Metastatic

**Session Data and Time:** Saturday, Jun 2, 8:00 - 11:30 a.m. CDT

**Location:** Hall A, Poster Board Number: #131

**Abstract Number and Title:** TPS1109, "AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer."

**Poster Session:** Breast Cancer—Metastatic

**Session Data and Time:** Saturday, Jun 2, 8:00 - 11:30 a.m. CDT

**Location:** Hall A, Poster Number: #185b

**Abstract Number and Title:** TPS3129, "The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3lg fusion protein) for advanced stage solid tumor entities."

**Poster Session:** Developmental Therapeutics—Immunotherapy

**Session Data and Time:** Monday, Jun 4, 8:00 - 11:30 a.m. CDT

**Location:** Hall A, Poster Board Number: #329a

**About the AIPAC clinical trial**

The ongoing AIPAC (Active Immunotherapy PAClitaxel) Phase IIb clinical trial is a European multi-centre study evaluating eftilagimod alpha ("efti" or "IMP321") in combination with paclitaxel in metastatic breast cancer (clinicaltrials.gov identifier NCT 02614833). To date, 33 out of a planned 34 clinical sites across Belgium, the Netherlands, Poland, Hungary, United Kingdom, France and Germany are now actively recruiting and treating patients. The study is expected to be fully recruited with 226 patients in third quarter of calendar 2018; first Progression Free Survival data are expected in calendar 2019.

### **About the INSIGHT clinical trial**

The on-going INSIGHT Phase I clinical trial is an investigator initiated, explorative, single centre, open-label, study evaluating the feasibility and safety of intra-tumoural, intra-peritoneal, and subcutaneous injections of efti for advanced stage solid tumour entities (clinicaltrials.gov identifier NCT03252938). The Lead Investigator of this clinical trial is Professor Doctor Salah-Eddin Al-Batran, the Medical Director of the IKF.

### **About Immunetep**

Immunetep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immunetep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immunetep's current lead product is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immunetep's large pharmaceutical partners. Immunetep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Immunetep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S. For further information please visit [www.immunetep.com](http://www.immunetep.com) or contact:

#### **U.S. Investors:**

Jay Campbell, Vice President of Business Development and Investor Relations, Immunetep Limited  
+1 (917) 860-9404; [jay.campbell@immunetep.com](mailto:jay.campbell@immunetep.com)

#### **Australian Investors/Media:**

Matthew Gregorowski, Citadel-MAGNUS  
+61 2 8234 0105; [mgregorowski@citadelmagnus.com](mailto:mgregorowski@citadelmagnus.com)

For personal use only